BCM-95® (CURCUGREEN®), 28 Mar 2022

[Rizaldy Taslim Pinzon, Fransiscus Buwana;

Potential Therapeutic Effects of Curcuma longa extract in Patients with Osteoarthritis: A Randomized Controlled Trial;

J. Pharm. Sci. & Res. Vol. 11(11), 2019, 3628-3633]

Osteoarthritis (OA) is the most common degenerative joint disorder in the elderly and a major public health problem in worldwide. Non-steroidal anti-inflammatory drug (NSAID) is a common medication given in OA patients, but its use was limited due to many side effects. Previous studies showed that Curcuma Longa extracts may exhibit benefic effects in the treatment of OA. To determine the effective and safety of Curcuma Longa extracts for reducing pain in patients with osteoarthritis. A randomized controlled trial (RCT) in OA patients. Subjects were randomized to 3 different group. Group I: CB extract (350 mg of Curcuma longa and 150 mg Boswellia serrata) and NSAID (400 mg ibuprofen or 50 mg diclofenac sodium), group II: CB extract, group III: NSAID. Each subject would be followed up 3 times: baseline, second weeks, fourth weeks after baseline. The pain severity was measured using visual analogue scale (VAS). The analysis is intention to treat based. There were 105 subjects enrolled at the study. Subjects were dominated by female (80%) with mean aged 63 years. Ninety-five subjects (group I: 36; group II: 29, group III: 30) remained for complete analysis. Group I showed the greatest reduction of VAS score after the second and fourth weeks of treatment (more than 50%). Group III has the least VAS score reduction after fourth weeks from baseline. There was statistically different of VAS score reduction between groups (P<0.001). The most frequent AE were reported from subjects in group III. CB extract is effective and safe for reducing pain in OA patients.